Industrial biotechnology for improved manufacture of medicinal alkaloids. Industrial biotechnology for improved manufacture of medicinal alkaloids. This project aims to develop a new semi-synthetic route for the manufacture of Codeine from Thebaine. Codeine is manufactured by the chemical conversion of poppy-derived Morphine, which is low yielding and environmentally unfriendly. This project will investigate and optimise two key enzymes in the biosynthetic pathway to Codeine and develop an innov ....Industrial biotechnology for improved manufacture of medicinal alkaloids. Industrial biotechnology for improved manufacture of medicinal alkaloids. This project aims to develop a new semi-synthetic route for the manufacture of Codeine from Thebaine. Codeine is manufactured by the chemical conversion of poppy-derived Morphine, which is low yielding and environmentally unfriendly. This project will investigate and optimise two key enzymes in the biosynthetic pathway to Codeine and develop an innovative bioreactor to achieve high yield. It will research industrial biotransformations, providing a greener and cheaper process for increased global access to Codeine. Australian opiate manufacturing is expected to benefit from value adding and increased flexibility introduced by a biotechnology approach.Read moreRead less
Industrial biotechnology for the manufacture of alkaloid pharmaceuticals. Drugs that treat opioid dependence and overdose are increasingly needed but their manufacture is difficult, inefficient and expensive. This project aims to develop enzymatic N-demethylation as a simpler and more sustainable approach to the manufacture and modification of opioid antagonists, alkaloids and other drug targets. It will increase our understanding of enzymatic N-demethylation and address engineering and biotechn ....Industrial biotechnology for the manufacture of alkaloid pharmaceuticals. Drugs that treat opioid dependence and overdose are increasingly needed but their manufacture is difficult, inefficient and expensive. This project aims to develop enzymatic N-demethylation as a simpler and more sustainable approach to the manufacture and modification of opioid antagonists, alkaloids and other drug targets. It will increase our understanding of enzymatic N-demethylation and address engineering and biotechnology challenges to improve yield and product isolation and concentration. Improvements in drug manufacturing processes will assist drug affected communities and industry will benefit from value adding, greater market share and flexibility, increased innovation and de-risked processes and new products. Read moreRead less